Ticagrelor: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Replaced content with " Category:Drugs")
No edit summary
Line 1: Line 1:
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443228756
| IUPAC_name = (1''S'',2''S'',3''R'',5''S'')-3-[7-[(1''R'',2''S'')-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
| image = Ticagrelor3.png
| width = 300
| image2 = Ticagrelor ball-and-stick animation.gif


[[Category:Drugs]]
<!--Clinical data-->
| tradename = Brilinta, Brilique, Possia
| MedlinePlus      = a611050
| licence_EU = Brilique
| licence_US = Ticagrelor
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_status =
| routes_of_administration = Oral
 
<!--Pharmacokinetic data-->
| bioavailability = 36%
| protein_bound = >99.7%
| metabolism = [[Hepatic]] ([[CYP3A4]])
| elimination_half-life = 7 hrs (ticagrelor), 8.5 hrs ([[active metabolite]] AR-C124910XX)
| excretion = [[Biliary]]
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 274693-27-5
| ATC_prefix = B01
| ATC_suffix = AC24
| ATC_supplemental =
| PubChem = 9871419
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = GLH0314RVC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09017
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 398435
 
<!--Chemical data-->
| chemical_formula =
| C=23 | H=28 | F=2 | N=6 | O=4 | S=1
| molecular_weight = 522.567 g/mol
| smiles = CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = OEKWJQXRCDYSHL-FNOIDJSQSA-N
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8047109
|  InChI = 1/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
|  InChIKey = OEKWJQXRCDYSHL-FNOIDJSQBW
| synonyms = AZD-6140
}}
 
__NOEDITSECTION____NOTOC__
{{CMG}} {{AE}}{{JH}}
{{SB}} [[Lopressor]], [[Toprol XL]]
 
==Overview==
 
'''Ticagrelor''' (trade name '''Brilinta''' in the US, '''Brilique''' and '''Possia''' in the EU) is a [[platelet aggregation inhibitor]] produced by [[AstraZeneca]]. The drug was approved for use in the [[European Union]] by the [[European Commission]] on December 3, 2010.<ref name="EPAR Brilique">{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001241/WC500100492.pdf|title=Assessment Report for Brilique|publisher=[[European Medicines Agency]]|date=January 2011}}</ref><ref>[http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002303/human_med_001399.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 European Public Assessment Report Possia]</ref> The drug was approved by the US [[Food and Drug Administration]] on July 20, 2011.<ref>{{cite web|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964.htm|title=FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes|publisher=FDA|date=20 July 2011}}</ref>
 
==Category==
 
P2Y12 platelet inhibitor, platelet aggregation inhibitor
 
==Prescribing Information==
 
===[[Brilinta tablet|Brilinta (ticagrelor) tablet]]===
 
==References==
 
{{reflist|2}}

Revision as of 17:35, 19 March 2014

Ticagrelor
File:Ticagrelor3.png
File:Ticagrelor ball-and-stick animation.gif
Clinical data
Trade namesBrilinta, Brilique, Possia
SynonymsAZD-6140
MedlinePlusa611050
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability36%
Protein binding>99.7%
MetabolismHepatic (CYP3A4)
Elimination half-life7 hrs (ticagrelor), 8.5 hrs (active metabolite AR-C124910XX)
ExcretionBiliary
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H28F2N6O4S
Molar mass522.567 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2] Synonyms / Brand Names: Lopressor, Toprol XL

Overview

Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.[1][2] The drug was approved by the US Food and Drug Administration on July 20, 2011.[3]

Category

P2Y12 platelet inhibitor, platelet aggregation inhibitor

Prescribing Information

Brilinta (ticagrelor) tablet

References

  1. ↑ "Assessment Report for Brilique" (PDF). European Medicines Agency. January 2011.
  2. ↑ European Public Assessment Report Possia
  3. ↑ "FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes". FDA. 20 July 2011.
Retrieved from "https://www.wikidoc.org/index.php?title=Ticagrelor&oldid=957866"